This phase I trial is designed to evaluate the safety and maximum tolerated dose (MTD) of a new oral drug, given in combination with a type of immunotherapy in patients with solid cancers.
This trial is treating patients with solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Open-label, Multicenter, Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies
Eligible patients will receive oral SAR442720 (also known as RMC-4630) with intravenous (IV) pembrolizumab once every 3 weeks (Q3W). The dose of SAR442720 will be escalated or de-escalated depending on the emerging safety data of the combination.
Recruiting Hospitals Read More